In both models, the beneficial effect of blocking type I IFN after administration was negated by blocking type II IFN simultaneously, which is in line with reports in patients with tumour defects in IFNγ signalling associated with acquired resistance to ICB31. This evidence concerns the gene IFNG and neoplasm.